Comparing the Immune-Genomic Effects of Vilazodone and Paroxetine in Late-Life Depression: A Pilot Study

Harris Eyre; Prabha Siddarth; Natalie Cyr; Hongyu Yang; Steve Cole; Malcolm Forbes; Helen Lavretsky

doi:10.1055/s-0043-107033

Pharmacopsychiatry, Table of Contents

Pharmacopsychiatry 2017; 50(06): 256-263
DOI: 10.1055/s-0043-107033

Original Paper

Comparing the Immune-Genomic Effects of Vilazodone and Paroxetine in Late-Life Depression: A Pilot Study

Harris Eyre

¹Semel Institute for Neuroscience and Human Behavior, UCLA, Los Angeles, California, United State of America (USA)

²Discipline of Psychiatry, University of Adelaide, Adelaide, South Australia, Australia

³Department of Psychiatry, University of Melbourne, Melbourne, Victoria, Australia

⁴IMPACT SRC, School of Medicine, Deakin University, Geelong, Victoria, Australia

,

Prabha Siddarth

¹Semel Institute for Neuroscience and Human Behavior, UCLA, Los Angeles, California, United State of America (USA)

,

Natalie Cyr

¹Semel Institute for Neuroscience and Human Behavior, UCLA, Los Angeles, California, United State of America (USA)

,

Hongyu Yang

⁵Ahmanson-Lovelace Brain Mapping Center, Department of Neurology, UCLA, Los Angeles, California, USA

,

Steve Cole

¹Semel Institute for Neuroscience and Human Behavior, UCLA, Los Angeles, California, United State of America (USA)

⁶Department of Medicine, Hematology-Oncology, UCLA, Los Angeles, California, USA

,

Malcolm Forbes

⁷School of Medicine, University of Queensland, Brisbane, Queensland, Australia

,

Helen Lavretsky

¹Semel Institute for Neuroscience and Human Behavior, UCLA, Los Angeles, California, United State of America (USA)

› Author Affiliations

Abstract

Background

Vilazodone is a novel antidepressant agent that combines selective serotonin (5-HT) reuptake inhibitor (SSRI) activity and 5-HT(1A) receptor partial agonist activity.

Objective

A pilot study was conducted to compare vilazodone (novel compound) and paroxetine (gold standard) on antidepressant effects, tolerability, and inflammation and immune modulation.

Methods

A 12-week, double-blind, randomized clinical trial was conducted with 56 nondemented older adults diagnosed with major depressive disorder (MDD). Between-group differences in mood, tolerability, and safety, as well as genomic markers of inflammation and immune modulation, were examined.

Results

Both treatment groups demonstrated similar improvement in depressed mood. Leukocyte gene expression profiles demonstrated reduction of specific proinflammatory gene transcripts and bioinformatic indications of reduced nuclear factor kappa B (NF-κB), activator protein (AP)-1, and cAMP response element binding (CREB) activity in the vilazodone group compared to the paroxetine group. Transcript origin analyses implicated monocytes and dendritic cells as the primary cellular origins of transcript reductions in the vilazodone-treated group.

Conclusions

Vilazodone’s antidepressant effects may be associated with reduction of proinflammatory gene expression and immune modulation. Further research is required.

Key words

geriatric depression - gene - antidepressant - immune - inflammation

Full Text

References

References
1 Ferrari AJ, Charlson FJ, Norman RE. et al. Burden of depressive disorders by country, sex, age, and year: Findings from the global burden of disease study 2010. PLoS Med 2013; 10: e1001547
2 Kok RM, Nolen WA, Heeren TJ. Efficacy of treatment in older depressed patients: A systematic review and meta-analysis of double-blind randomized controlled trials with antidepressants. J Affect Disord. 2012; 141: 103-115
3 Rickels K, Athanasiou M, Robinson DS. et al. Evidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: A randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2009; 70: 326-333
4 FDA . VIlazodone hydrochloride approval for major depressive disorder. FDA; 2011
5 Khan A, Cutler AJ, Kajdasz DK. et al. A randomized, double-blind, placebo-controlled, 8-week study of vilazodone, a serotonergic agent for the treatment of major depressive disorder. J Clin Psychiatry. 2011; 72: 441-447
6 Robinson DS, Kajdasz DK, Gallipoli S. et al. A 1-year, open-label study assessing the safety and tolerability of vilazodone in patients with major depressive disorder. J Clin Psychopharmacol. 2011; 31: 643-646
7 Lundmark J, Scheel Thomsen I, Fjord-Larsen T. et al. Paroxetine: pharmacokinetic and antidepressant effect in the elderly. Acta Psychiatr Scand Suppl. 1989; 350: 76-80
8 Dechant KL, Clissold SP. Paroxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness. Drugs 1991; 41: 225-253
9 Muller N, Hofschuster E, Ackenheil M. et al. Investigations of the cellular immunity during depression and the free interval: Evidence for an immune activation in affective psychosis. Prog Neuropsychopharmacol Biol Psychiatry 1993; 17: 713-730
10 Hannestad J, Dellagioia N, Bloch M. The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: A meta-analysis. Neuropsychopharmacology 2011; 36: 2452-2459
11 Eyre HA, Stuart MJ, Baune BT. A phase-specific neuroimmune model of clinical depression. Prog Neuropsychopharmacol Biol Psychiatry. 2014; 54: 265-274
12 Ransohoff RM, Brown MA. Innate immunity in the central nervous system. J Clin Invest. 2012; 122: 1164-1171
13 Eyre H, Baune BT. Neuroplastic changes in depression: A role for the immune system. Psychoneuroendocrinology 2012; 37: 1397-1416
14 Eyre HA, Lavretsky H, Kartika J. et al. Modulatory effects of antidepressant classes on the innate and adaptive immune system in depression. Pharmacopsychiatry 2016; 49: 85-96
15 Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960; 23: 56-62
16 Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12: 189-198
17 Yesavage JA. Depression in the elderly. How to recognize masked symptoms and choose appropriate therapy. Postgrad Med. 1992; 91: 255-258 261
18 Guy W. Clinical Global Impressions (CGI). In: Services UDoHaH . ed. ECDEU Assessment Manual for Psychopharmacology. Rockville: Alcohol drug abuse and mental health administration, NIMPH Psychopharmacology Research Branch; 1976: 218-222
19 American Heart Association . Stroke risk factor prediction chart. Dallas: American Heart Association; 1990
20 American Heart Association . Stroke risk factor prediction chart. Dallas, TX: 1990
21 Schone W, Ludwig M. A double-blind study of paroxetine compared with fluoxetine in geriatric patients with major depression. J Clin Psychopharmacol. 1993; 13: 34S-39S
22 Schatzberg AF, Kremer C, Rodrigues HE. et al. Double-blind, randomized comparison of mirtazapine and paroxetine in elderly depressed patients. Am J Geriatr Psychiatry 2002; 10: 541-550
23 Lingjaerde O, Ahlfors UG, Bech P. et al. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl. 1987; 334: 1-100
24 Fredrickson BL, Grewen KM, Coffey KA. et al. A functional genomic perspective on human well-being. Proc Natl Acad Sci USA. 2013; 110: 13684-13689
25 Cole SW, Yan W, Galic Z. et al. Expression-based monitoring of transcription factor activity: The TELiS database. Bioinformatics 2005; 21: 803-810
26 Cole SW, Hawkley LC, Arevalo JM. et al. Transcript origin analysis identifies antigen-presenting cells as primary targets of socially regulated gene expression in leukocytes. Proc Natl Acad Sci USA. 2011; 108: 3080-3085
27 Efron B, Tibshirani RJ. An Introduction to the Bootstrap. New York: Chapman & Hall; 1993
28 Uher R, Tansey KE, Dew T. et al. An inflammatory biomarker as a differential predictor of outcome of depression treatment with escitalopram and nortriptyline. Am J Psychiatry. 2014; 171: 1278-1286
29 Tynan RJ, Weidenhofer J, Hinwood M. et al. A comparative examination of the anti-inflammatory effects of SSRI and SNRI antidepressants on LPS stimulated microglia. Brain Behav Immun. 2012; 26: 469-479
30 Prinz M, Priller J. Microglia and brain macrophages in the molecular age: from origin to neuropsychiatric disease. Nat Rev Neurosci. 2014; 15: 300-312
31 Butovsky O, Kunis G, Koronyo-Hamaoui M. et al. Selective ablation of bone marrow-derived dendritic cells increases amyloid plaques in a mouse Alzheimer’s disease model. Eur J Neurosci. 2007; 26: 413-416
32 Rook GA, Lowry CA. The hygiene hypothesis and psychiatric disorders. Trends Immunol. 2008; 29: 150-158
33 Leonard B, Maes M. Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression. Neurosci Biobehav Rev. 2012; 36: 764-785
34 Banchereau J, Briere F, Caux C. et al. Immunobiology of dendritic cells. Annu Rev Immunol. 2000; 18: 767-811
35 Pashenkov M, Teleshova N, Link H. Inflammation in the central nervous system: the role for dendritic cells. Brain Pathol. 2003; 13: 23-33
36 D’Agostino PM, Gottfried-Blackmore A, Anandasabapathy N. et al. Brain dendritic cells: Biology and pathology. Acta Neuropathol. 2012; 124: 599-614
37 Alexopoulos GS. Depression in the elderly. Lancet 2005; 365: 1961-1970
38 Disabato BM, Morris C, Hranilovich J. et al. Comparison of brain structural variables, neuropsychological factors, and treatment outcome in early-onset versus late-onset late-life depression. Am J Geriatr Psychiatry 2014; 22: 1039-1046
39 Sachs-Ericsson N, Corsentino E, Moxley J. et al. A longitudinal study of differences in late- and early-onset geriatric depression: Depressive symptoms and psychosocial, cognitive, and neurological functioning. Aging Ment Health. 2013; 17: 1-11
40 Janssen J, Hulshoff Pol HE, de Leeuw FE. et al. Hippocampal volume and subcortical white matter lesions in late life depression: Comparison of early and late onset depression. J Neurol Neurosurg Psychiatry. 2007; 78: 638-640
41 Rapp MA, Dahlman K, Sano M. et al. Neuropsychological differences between late-onset and recurrent geriatric major depression. Am J Psychiatry. 2005; 162: 691-698